TY - JOUR T1 - Late Breaking Abstract - Retrospective observational analysis of platypnea- orthodeoxia syndrome (POS) in long COVID over 5 months at a pulmonary medicine unit JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA3895 VL - 58 IS - suppl 65 SP - PA3895 AU - Tanya Athavale AU - Amita Athavale AU - Kartik Joshi AU - Sushmitha Ravindran AU - Ayushi Trehan AU - Pooja Khupse AU - Mahesh Jansari AU - Sonal Karpe Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA3895.abstract N2 - Introduction: Platypnoea-Orthodeoxia syndrome (POS) is the presence of postural hypoxaemia and breathlessness in supine position and has been described in COVID-19 ARDS survivors by Tan l et al1 Respir Physiol Neurobiol. 2020;282:103515, and at presentation in moderate COVID-19 by Athavale et al2 J Assoc Physicians India. 2021 June;69(6). We studied clinical characteristics and prevalence of POS in patients with long COVID requiring indoor care.Methodology: We retrospectively analysed indoor records of 19 patients admitted with long COVID (signs and symptoms beyond 4 weeks of COVID-19 infection) to our pulmonary care unit from January 2021 to May 2021. Clinical profiles of patients with and without POS were compared.Results: 7 (36.8%) patients had POS with a mean desaturation of 8% in sitting compared to supine position. 7(100%) patients with POS and 8(66%) without POS had received Remdesivir. 3 (42.8%) patients with POS and 4(33%) without POS had received anti-IL-6R biologic therapy. Patients with POS were similar in age to those without POS (58 v/s 50.5 years; p>0.5), had lower mean C-reactive protein level (11.8 v/s 59.1 mg/L;p <0.05), higher mean CT severity score (20.5 v/s 14.8;p<0.05) and similar mean lactate dehydrogenase levels (787 v/s 987 U/L;p=0.45). A positive D-dimer assay (age-adjusted) was commoner in POS group (7 v/s 3; Fishers exact test, p<0.05). Median days to resolution of POS were 24 (range 10-45), which is more than the 17 days in the study by Tan et al1.Conclusion: POS is a common debilitating feature of long COVID and further study is required to assess presence of POS as a prognostic indicator in long COVID.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3895.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -